Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Head and Neck Cancer

Free Subscription Articles published in Radiother Oncol Retrieve available abstracts of 229 articles: HTML format

Single Articles

September 2025
1. LIU Y, Su Y, Peng J, Zhang W, et al
   A multidimensional deep ensemble learning model predicts pathological response and outcomes in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy from pretreatment CT imaging: A multicenter study.
   Radiother Oncol. 2025 Sep 10:111133. doi: 10.1016/j.radonc.2025.111133.
   PubMed     Abstract available
   
   
   
2. GAU M, Alfaraj FA, Huang SH, O'Sullivan B, et al
   Unilateral vs bilateral neck irradiation: The importance of careful patient selection in tailoring radiation therapy for lateralized palatine-tonsil and non-palatine-tonsil oropharyngeal carcinoma.
   Radiother Oncol. 2025;210:111049.
   PubMed     Abstract available
   
   
   
3. CHEUNG BMF, Yuen KK, Luk MY, Leung DKC, et al
   Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints.
   Radiother Oncol. 2025;210:111009.
   PubMed     Abstract available
   
   
   August 2025
4. WONG HCY, Karam I, Corbin K, Tse SSW, et al
   Bao Yuan Gao vs. Calendula cream for radiotherapy-induced skin toxicity in head and neck cancer: A randomized controlled trial - A biased negative trial essentially.
   Radiother Oncol. 2025;211:111109.
   PubMed    
   
   
   
5. HANSEN CR, Samsoe E, Smulders B, Sand HMB, et al
   Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.
   Radiother Oncol. 2025;211:111096.
   PubMed     Abstract available
   
   
   
6. SILVERWOOD SM, Carlson CM, Zhu H, Biancia CD, et al
   Enhancing IMRT/VMAT Competencies in LMICs globally within radiation physicists through remote training.
   Radiother Oncol. 2025;209:110957.
   PubMed     Abstract available
   
   
   
7. HORBERGER F, Petersson K, Ceberg S, Back S, et al
   Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study.
   Radiother Oncol. 2025;209:110947.
   PubMed     Abstract available
   
   
   
8. LASKAR SG, Sood S, Chatterjee A, Sinha S, et al
   Presentation and outcomes of second primary malignancies (SPMs) in locally advanced oral cavity squamous carcinoma (LA-OSCC): Secondary analysis of a phase III randomised control trial (NCT00193843).
   Radiother Oncol. 2025;209:110944.
   PubMed     Abstract available
   
   
   
9. MALONE C, Ryan S, Nicholson J, 'Maolalai RO, et al
   Intrafraction motion stability of open vs. closed facemasks in head and neck radiotherapy: Insights from the OPEN phase III trial.
   Radiother Oncol. 2025;209:110941.
   PubMed     Abstract available
   
   
   
10. TUO A, Moon DH, Avkshtol V, Shah JL, et al
    Associations between dosimetry and patient-reported outcomes in oropharyngeal cancer: post hoc analysis of elective neck de-escalation trials.
    Radiother Oncol. 2025;209:110933.
    PubMed     Abstract available
    
    
    July 2025
11. YANG C, Shen M, Long L, Meng Z, et al
    The potential value of IVIM MR for radiation-related hypothyroidism in nasopharyngeal carcinoma.
    Radiother Oncol. 2025;211:111065.
    PubMed     Abstract available
    
    
    
12. CHEN ZH, Han X, Lin L, Lin GY, et al
    Harnessing deep learning to optimize induction chemotherapy choices in nasopharyngeal carcinoma.
    Radiother Oncol. 2025;211:111047.
    PubMed     Abstract available
    
    
    
13. ZHENG S, Liu Y, He Z, He S, et al
    CNG (Collaborative Nasopharyngeal Carcinoma Group) stage: Improved prognostic stratification of nasopharyngeal carcinoma and association with Epstein-Barr virus DNA in the intensity-modulated radiation therapy era.
    Radiother Oncol. 2025;210:111051.
    PubMed     Abstract available
    
    
    
14. PETRELLI F, Trevisan F, Nardone M, Carioli D, et al
    Non-cisplatin concurrent agents plus definitive radiotherapy for locally advanced head and neck cancer: A network meta-analysis of randomized studies.
    Radiother Oncol. 2025 Jul 14:111033. doi: 10.1016/j.radonc.2025.111033.
    PubMed     Abstract available
    
    
    
15. DE LEEUW ALMP, Hoebers FJP, Giralt J, Tao Y, et al
    Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial.
    Radiother Oncol. 2025;210:111044.
    PubMed     Abstract available
    
    
    
16. JENSEN K, Holm AIS, Eriksen JG, Skyt PS, et al
    Danish Head and Neck Cancer Group (DAHANCA) Radiotherapy Quality Assurance Guidelines 2025. Update and new chapters: Planning of complex targets, hypofractionation, planning of reirradiation, target definition after induction chemotherapy, and clarifi
    Radiother Oncol. 2025;210:111028.
    PubMed    
    
    
    
17. PERREARD M, Florent R, Divoux J, Bastit V, et al
    Use of patient-derived tumor organoids from head and neck squamous cell carcinoma for the evaluation of the differential effect of carbon ions over X-rays.
    Radiother Oncol. 2025 Jul 3:111026. doi: 10.1016/j.radonc.2025.111026.
    PubMed     Abstract available
    
    
    
18. LAUWENS L, Ribeiro MF, Zegers CML, Hoyer M, et al
    Systematic review of MRI alterations in the brain following proton and photon radiation therapy: Towards a uniform European Particle Therapy Network (EPTN) definition.
    Radiother Oncol. 2025;208:110936.
    PubMed     Abstract available
    
    
    
19. KAFFEY Z, Mirbahaeddin S, Wahid K, Kamel S, et al
    Radiographic classification of mandibular osteoradionecrosis: A blinded prospective multi-disciplinary interobserver diagnostic performance study.
    Radiother Oncol. 2025;208:110917.
    PubMed     Abstract available
    
    
    
20. ESSERS M, Mesch L, Beugeling M, de Wee E, et al
    Goodbye face masks! Accurate head and neck radiotherapy using individual dorsal shells and surface guidance.
    Radiother Oncol. 2025;208:110909.
    PubMed     Abstract available
    
    
    
21. KREIKE B, Al-Mamgani A, van Werkhoven E, Beugeling M, et al
    Postoperative radiotherapy for oral cavity cancer with or without elective neck radiotherapy of the pN0 en bloc dissected neck: oncologic outcomes and late toxicity.
    Radiother Oncol. 2025;208:110896.
    PubMed     Abstract available
    
    
    
22. LIU ZQ, Zang SB, OuYang PY, Jing BZ, et al
    Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy.
    Radiother Oncol. 2025 Jul 1:111010. doi: 10.1016/j.radonc.2025.111010.
    PubMed     Abstract available
    
    
    
23. YANG F, Wang D, Su Y, Tang J, et al
    The dynamic changes of glymphatic function at different post-radiotherapy stages in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Jul 1:111012. doi: 10.1016/j.radonc.2025.111012.
    PubMed     Abstract available
    
    
    June 2025
24. POPULAIRE P, Defraene G, Liu Y, Titt U, et al
    Dose to the left ventricle is associated to the risk of acute cardiac toxicity in patients with esophageal cancer undergoing trimodality treatment.
    Radiother Oncol. 2025;209:111002.
    PubMed     Abstract available
    
    
    
25. ZHENG Q, Yu X, Pan W, Ai Y, et al
    Deep learning dosiomics in grade 4 radiation-induced lymphopenia prediction in radiotherapy for esophageal cancer: a multi-center study.
    Radiother Oncol. 2025;209:110995.
    PubMed     Abstract available
    
    
    
26. LI Y, Liang J, Fu G, Pan J, et al
    Non-linear early rapid hippocampal atrophy and associated microstructural injury in patients with nasopharyngeal carcinoma after radiotherapy: Implications for hippocampal protection.
    Radiother Oncol. 2025;209:110997.
    PubMed     Abstract available
    
    
    
27. LI J, He HG, Guan C, Ding Y, et al
    Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.
    Radiother Oncol. 2025;209:110993.
    PubMed     Abstract available
    
    
    
28. MOHARRAMI M, Watson E, Huang SH, Madathil S, et al
    Defining the optimal radiation thresholds for Stratifying jaw osteoradionecrosis risk in head and neck cancer.
    Radiother Oncol. 2025;209:110996.
    PubMed     Abstract available
    
    
    
29. BACHMANN N, Ahmadsei M, Hurlimann M, Gabrys HS, et al
    Cone-beam computed tomography-based online adaptive radiotherapy of esophageal cancer in the neoadjuvant setting: Dosimetric analysis, toxicity and treatment response.
    Radiother Oncol. 2025;209:110981.
    PubMed     Abstract available
    
    
    
30. NGAN TH, Yeh SH, Tien HJ, Hsu CX, et al
    Bao Yuan Gao vs. Calendula cream for radiotherapy-induced skin toxicity in head and neck cancer: A randomized controlled trial.
    Radiother Oncol. 2025;209:110976.
    PubMed     Abstract available
    
    
    
31. HUMBERT-VIDAN L, Kamel S, Wentzel A, Kaffey Z, et al
    Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts.
    Radiother Oncol. 2025;207:110890.
    PubMed     Abstract available
    
    
    
32. EVANS M, Bonomo P, Chan PC, Chua MLK, et al
    Post-operative radiotherapy for oral cavity squamous cell carcinoma: Review of the data guiding the selection and the delineation of post-operative target volumes.
    Radiother Oncol. 2025;207:110880.
    PubMed     Abstract available
    
    
    
33. YARLAGADDA S, Rohe RM, McNeill V, Nemec JR, et al
    Tubarial gland sparing for oropharyngeal cancer: Feasibility with intensity modulated proton therapy & intensity modulated radiation therapy.
    Radiother Oncol. 2025;207:110882.
    PubMed     Abstract available
    
    
    
34. GAWRYSZUK A, van der Laan HP, Vergeer MR, Veening M, et al
    Improved NTCP model for late radiation-induced aspiration based on dose delivered to specific aspiration-related OARs.
    Radiother Oncol. 2025;207:110871.
    PubMed     Abstract available
    
    
    
35. HUGHES A, Johnny C, Huang SH, Su J, et al
    The prognostic and predictive value of pre-treatment hematologic markers for oropharyngeal carcinoma stratified by HPV status and treated with definitive (chemo) radiation.
    Radiother Oncol. 2025;207:110851.
    PubMed     Abstract available
    
    
    
36. MA B, Guo J, Dijk LVV, Langendijk JA, et al
    PET and CT based DenseNet outperforms advanced deep learning models for outcome prediction of oropharyngeal cancer.
    Radiother Oncol. 2025;207:110852.
    PubMed     Abstract available
    
    
    May 2025
37. XIANG Z, Yu X, Lin S, Wang D, et al
    Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.
    Radiother Oncol. 2025 May 22:110951. doi: 10.1016/j.radonc.2025.110951.
    PubMed     Abstract available
    
    
    
38. YI X, Yu X, Li C, Li J, et al
    Deep learning Radiopathomics based on pretreatment MRI and whole slide images for predicting overall survival in locally advanced nasopharyngeal carcinoma.
    Radiother Oncol. 2025;209:110949.
    PubMed     Abstract available
    
    
    
39. DING J, Yin X, Lin Y, Liao X, et al
    Transforming the management of radiotherapy-induced hypothyroidism in nasopharyngeal carcinoma through an Innovative individualized radiation dosage model: A multicenter retrospective analysis.
    Radiother Oncol. 2025;208:110943.
    PubMed     Abstract available
    
    
    
40. CHEN SY, Duan XT, Xie RL, Han YQ, et al
    Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 May 2:110913. doi: 10.1016/j.radonc.2025.110913.
    PubMed     Abstract available
    
    
    
41. ARENDS C, de Veij Mestdagh P, Al-Mamgani A, Stuiver M, et al
    Severity of internal lymphedema in unilateral or bilateral radiotherapy patients: An exploratory study.
    Radiother Oncol. 2025;206:110834.
    PubMed     Abstract available
    
    
    
42. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
    'iCycle-pBAO': Automated patient-specific beam-angle selection in proton therapy applied to oropharyngeal cancer.
    Radiother Oncol. 2025;206:110799.
    PubMed     Abstract available
    
    
    
43. CARSUZAA F, Favier V, Seguin L, Turri-Zanoni M, et al
    Consensus for a postoperative atlas of sinonasal substructures from a modified Delphi study to guide radiotherapy in sinonasal malignancies.
    Radiother Oncol. 2025;206:110784.
    PubMed     Abstract available
    
    
    
44. YANG J, Liu C, Zuo Z, Cao F, et al
    Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.
    Radiother Oncol. 2025;206:110797.
    PubMed     Abstract available
    
    
    April 2025
45. YAN Y, Zhao F
    Response to the commentary on "Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning" by Mohammad Zahid, and Heiko Enderling.
    Radiother Oncol. 2025;208:110903.
    PubMed    
    
    
    
46. ERIKSEN JG, Maare C, Johansen J, Primdahl H, et al
    DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.
    Radiother Oncol. 2025 Apr 19:110899. doi: 10.1016/j.radonc.2025.110899.
    PubMed     Abstract available
    
    
    
47. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers FJP, et al
    Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma.
    Radiother Oncol. 2025 Apr 17:110900. doi: 10.1016/j.radonc.2025.110900.
    PubMed     Abstract available
    
    
    
48. WANG Z, Li L, Wu Y, Liu Z, et al
    Development and validation of Prediction models for radiation-induced hypoglossal neuropathy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Apr 8:110887. doi: 10.1016/j.radonc.2025.110887.
    PubMed     Abstract available
    
    
    
49. HIRAOKA S, Hirashima H, Nakamura M, Tanaka F, et al
    Integration test of biaxially rotational dynamic-radiation therapy for nasopharyngeal carcinoma: Efficacy evaluation and dosimetric analysis.
    Radiother Oncol. 2025;207:110879.
    PubMed     Abstract available
    
    
    
50. YANG F, Peng W, Wei H, Li X, et al
    Pretreatment arterial spin labeling combined with radiological depth of invasion predicts treatment outcome in nonmetastatic NPC.
    Radiother Oncol. 2025;205:110765.
    PubMed     Abstract available
    
    
    
51. LAUWERS I, Capala M, Kaushik S, Rusko L, et al
    Synthetic CT generation using Zero TE MR for head-and-neck radiotherapy.
    Radiother Oncol. 2025;205:110762.
    PubMed     Abstract available
    
    
    
52. LIAO CY, Maniscalco AM, Zhao H, Bai T, et al
    Contour uncertainty assessment for MD-omitted daily adaptive online head and neck radiotherapy.
    Radiother Oncol. 2025;205:110707.
    PubMed     Abstract available
    
    
    March 2025
53. ZENG Y, Hu Y, Wang L, Liao Z, et al
    Control of dental calculus Prevents severe Radiation-Induced oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2025 Mar 27:110872. doi: 10.1016/j.radonc.2025.110872.
    PubMed     Abstract available
    
    
    
54. LI R, Wang X, Luo J, Bai H, et al
    Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.
    Radiother Oncol. 2025;207:110867.
    PubMed     Abstract available
    
    
    
55. YAN Y, Sun X, Chen Y, Sun Z, et al
    Optimizing fractionation schedules for de-escalation radiotherapy in head and neck cancers using deep reinforcement learning.
    Radiother Oncol. 2025;207:110833.
    PubMed     Abstract available
    
    
    
56. KRISTENSEN MH, Nielsen SB, Alsner J, Sander Holm AI, et al
    A systematic review and proportional meta-analysis of image-based pattern of loco-regional failure analyses outcomes in head and neck squamous cell carcinoma.
    Radiother Oncol. 2025 Mar 13:110838. doi: 10.1016/j.radonc.2025.110838.
    PubMed     Abstract available
    
    
    
57. ZAYED S, Lang P, Read N, Correa RJM, et al
    Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial.
    Radiother Oncol. 2025 Mar 5:110831. doi: 10.1016/j.radonc.2025.110831.
    PubMed     Abstract available
    
    
    
58. FELICIANI G, Licciardello T, Guidi C, Del Duca M, et al
    Comparison of HDR-brachytherapy and tomotherapy for the treatment of non-melanoma skin cancers of the head and neck.
    Radiother Oncol. 2025;204:110703.
    PubMed     Abstract available
    
    
    February 2025
59. ANTUNES J, Young T, Pittock D, Jacobs P, et al
    Assessing multiple MRI sequences in deep learning-based synthetic CT generation for MR-only radiation therapy of head and neck cancers.
    Radiother Oncol. 2025 Feb 8:110782. doi: 10.1016/j.radonc.2025.110782.
    PubMed     Abstract available
    
    
    
60. VAN DER LAAN HP, Gawryszuk A, van der Schaaf A, Langendijk JA, et al
    Risk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study.
    Radiother Oncol. 2025;203:110698.
    PubMed     Abstract available
    
    
    January 2025
61. WAN D, Liu Q, Wei JS
    Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study".
    Radiother Oncol. 2025;205:110767.
    PubMed    
    
    
    
62. ZHAO C, Miao J
    Response to Dr. Dan Wan, Qing Liu, and Jia-Sha Wei's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Comment on "Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiat
    Radiother Oncol. 2025 Jan 30:110768. doi: 10.1016/j.radonc.2025.110768.
    PubMed    
    
    
    
63. ZHONG J, Chen H, Chen X, Ma N, et al
    Identifying adverse nodal features associated with poor prognosis in stage IB nasopharyngeal carcinoma patients based on the 9th AJCC/UICC staging system: Implications for treatment intensification.
    Radiother Oncol. 2025;205:110747.
    PubMed     Abstract available
    
    
    
64. NEH H, de Vette SPM, Stoffers RH, Zhou G, et al
    Normal tissue complication probability model predicting taste impairment in head and neck cancer patients: Evaluating the taste bud bearing tongue mucosa as a predictor.
    Radiother Oncol. 2025 Jan 28:110746. doi: 10.1016/j.radonc.2025.110746.
    PubMed     Abstract available
    
    
    
65. TORAIH E, Hussein M, Elshazli R, Abdelmaksoud A, et al
    Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis.
    Radiother Oncol. 2025;205:110706.
    PubMed     Abstract available
    
    
    
66. RAJENDRAN P, Yang Y, Niedermayr TR, Gensheimer M, et al
    Large language model-augmented learning for auto-delineation of treatment targets in head-and-neck cancer radiotherapy.
    Radiother Oncol. 2025;205:110740.
    PubMed     Abstract available
    
    
    
67. NERICH V, Falcoz A, Nadin L, Meurisse A, et al
    Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer.
    Radiother Oncol. 2025;204:110726.
    PubMed     Abstract available
    
    
    
68. CHEN L, Li J, Li K, Hu J, et al
    Corrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy" [Radiother. Oncol. 190 (2024) 109985].
    Radiother Oncol. 2025;204:110719.
    PubMed    
    
    
    
69. LU T, Gao X, Yu Z, Liu L, et al
    Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation Therapy: 3 years' experience.
    Radiother Oncol. 2025;204:110713.
    PubMed     Abstract available
    
    
    
70. KAMPEL L, Feldstein S, Tsuriel S, Trejo LL, et al
    TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma.
    Radiother Oncol. 2025;204:110714.
    PubMed     Abstract available
    
    
    
71. MENG X, Ju Z, Sakai M, Li Y, et al
    Normal tissue complication probability model for acute oral mucositis in patients with head and neck cancer undergoing carbon ion radiation therapy based on dosimetry, radiomics, and dosiomics.
    Radiother Oncol. 2025;204:110709.
    PubMed     Abstract available
    
    
    
72. ZHANG L, Zhang Z, Wang Y, Zhu Y, et al
    Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy.
    Radiother Oncol. 2025;204:110712.
    PubMed     Abstract available
    
    
    
73. FENSKE J, Steffen C, Mrosk F, Lampert P, et al
    A critical reflection of radiotherapy on osseous free flaps in mandibular segmental resection and immediate reconstruction in locally advanced oral squamous cell carcinoma: A cohort study.
    Radiother Oncol. 2025;202:110652.
    PubMed     Abstract available
    
    
    
74. LIU Y, Chen Z, Zhou Q, Shang X, et al
    A feasibility study of dose-band prediction in radiation therapy: Predicting a spectrum of plan dose.
    Radiother Oncol. 2025;202:110593.
    PubMed     Abstract available
    
    
    
75. BRONK JK, Augustyn A, Mohamed ASR, David Fuller C, et al
    Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.
    Radiother Oncol. 2025;202:110602.
    PubMed     Abstract available
    
    
    
76. CHUNG CV, Khan MS, Olanrewaju A, Pham M, et al
    Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sites.
    Radiother Oncol. 2025;202:110609.
    PubMed     Abstract available
    
    
    December 2024
77. WINTER RM, Boeke S, Leibfarth S, Habrich J, et al
    Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer.
    Radiother Oncol. 2024;204:110702.
    PubMed     Abstract available
    
    
    
78. RUHLE A, Weymann M, Behrens M, Olbrich J, et al
    Predicting cisplatin tolerability in older adults with head and neck cancer - Insights for improved chemoradiation outcomes.
    Radiother Oncol. 2024 Dec 24:110697. doi: 10.1016/j.radonc.2024.110697.
    PubMed     Abstract available
    
    
    
79. GIRAUD P, Guihard S, Thureau S, Guilbert P, et al
    Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers.
    Radiother Oncol. 2024 Dec 21:110693. doi: 10.1016/j.radonc.2024.110693.
    PubMed     Abstract available
    
    
    
80. HE SQ, Liu GY, Yu YH, Wang L, et al
    Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
    Radiother Oncol. 2024 Dec 19:110687. doi: 10.1016/j.radonc.2024.110687.
    PubMed     Abstract available
    
    
    
81. HUANG X, Lin K, Chen W, Zhang D, et al
    Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1alpha-HILPDA axis.
    Radiother Oncol. 2024 Dec 19:110686. doi: 10.1016/j.radonc.2024.110686.
    PubMed     Abstract available
    
    
    
82. ZHANG S, Yan L, Li R, Zhao Y, et al
    Development and validation of a nomogram to predict overall survival in patients with External auditory canal cancer.
    Radiother Oncol. 2024 Dec 19:110691. doi: 10.1016/j.radonc.2024.110691.
    PubMed     Abstract available
    
    
    
83. KOCH A, Reinhardt P, Elicin O, Aebersold DM, et al
    Predictive biomarkers of radiotherapy- related dermatitis, xerostomia, mucositis and dysphagia in head and neck cancer: A systematic review.
    Radiother Oncol. 2024 Dec 18:110689. doi: 10.1016/j.radonc.2024.110689.
    PubMed     Abstract available
    
    
    
84. LIANG JL, Wen YF, Huang YP, Guo J, et al
    A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study.
    Radiother Oncol. 2024;203:110660.
    PubMed     Abstract available
    
    
    
85. LI R, Zhao Y, Wu K, Li H, et al
    p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?
    Radiother Oncol. 2024;201:110578.
    PubMed     Abstract available
    
    
    
86. OUD M, Breedveld S, Gizynska M, Chen YH, et al
    Dosimetric advantages of adaptive IMPT vs. Enhanced workload and treatment time - A need for automation.
    Radiother Oncol. 2024;201:110548.
    PubMed     Abstract available
    
    
    
87. GUINOT JL, Bacorro W, Budrukkar A, Bussu F, et al
    GEC-ESTRO recommendations for head & neck cancer brachytherapy (interventional radiotherapy): 2nd update with focus on HDR and PDR.
    Radiother Oncol. 2024;201:110533.
    PubMed     Abstract available
    
    
    November 2024
88. MALLICK S
    Response to "Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma".
    Radiother Oncol. 2024;202:110656.
    PubMed    
    
    
    
89. SHI X, Hui B, Wang Y, Lu Y, et al
    Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma.
    Radiother Oncol. 2024 Nov 29:110655. doi: 10.1016/j.radonc.2024.110655.
    PubMed    
    
    
    
90. JIMENEZ-LABAIG P, Aymerich C, Rullan A, Cacicedo J, et al
    Prevalence of depressive and anxiety symptoms in patients with head and neck cancer undergoing radiotherapy: A systematic review and meta-analysis of longitudinal studies.
    Radiother Oncol. 2024;202:110649.
    PubMed     Abstract available
    
    
    
91. WU CN, Wang JD, Chen WC, Lin CY, et al
    Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study.
    Radiother Oncol. 2024 Nov 23:110648. doi: 10.1016/j.radonc.2024.110648.
    PubMed     Abstract available
    
    
    
92. LIU M, Pang B, Chen S, Zeng Y, et al
    Deep learning-based multiple-CT optimization: An adaptive treatment planning approach to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers.
    Radiother Oncol. 2024;202:110650.
    PubMed     Abstract available
    
    
    
93. URSINO S, Malfatti G, Felice F, Bonomo P, et al
    Deglutition preservation after swallowing (Swoars)-sparing IMRT in head and neck cancers: Definitive results of A multicenter prospective study of the italian association of radiotherapy and clinical oncology (Airo).
    Radiother Oncol. 2024 Nov 22:110651. doi: 10.1016/j.radonc.2024.110651.
    PubMed     Abstract available
    
    
    
94. HUANG LW, Pan JW, Li B, Wu WX, et al
    Evaluation of radiation induced brain injury in nasopharyngeal carcinoma patients based on multi-parameter quantitative MRI: A prospective longitudinal study.
    Radiother Oncol. 2024 Nov 11:110621. doi: 10.1016/j.radonc.2024.110621.
    PubMed     Abstract available
    
    
    
95. ZHU MY, Wu HJ, Fang T, Zhang GS, et al
    Risk factors of level Ib lymph node metastasis and clinical outcome of its selectively prophylactic irradiation in nasopharyngeal carcinoma: A real-world study.
    Radiother Oncol. 2024 Nov 11:110620. doi: 10.1016/j.radonc.2024.110620.
    PubMed     Abstract available
    
    
    
96. MALLICK S, Dagar A, Ghosh A, Aashita, et al
    Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial.
    Radiother Oncol. 2024 Nov 8:110611. doi: 10.1016/j.radonc.2024.110611.
    PubMed     Abstract available
    
    
    
97. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
    Radiother Oncol. 2024 Nov 8:110612. doi: 10.1016/j.radonc.2024.110612.
    PubMed     Abstract available
    
    
    
98. VAN BRUGGEN IG, van Dijk M, Brinkman-Akker MJ, Lofman F, et al
    Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study.
    Radiother Oncol. 2024;200:110522.
    PubMed     Abstract available
    
    
    
99. YANG WC, Koto M, Ikawa H, Imai R, et al
    Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma.
    Radiother Oncol. 2024;200:110511.
    PubMed     Abstract available
    
    
    
100. XU MH, Dou JP, Guo MH, Yi WQ, et al
     Risk factors for recurrent laryngeal nerve injury in microwave ablation of thyroid nodules: A multicenter study.
     Radiother Oncol. 2024;200:110516.
     PubMed     Abstract available
     
     
     
101. LUDWIG R, Werlen S, Barbatei D, Widmer L, et al
     Patterns of lymph node involvement for oral cavity squamous cell carcinoma.
     Radiother Oncol. 2024;200:110474.
     PubMed     Abstract available
     
     
     
102. CHEN AM
     De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much...and what next?
     Radiother Oncol. 2024;200:110373.
     PubMed     Abstract available
     
     
     
103. CHEN B, Zhan Z, Xu Y, Yu S, et al
     Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.
     Radiother Oncol. 2024 Nov 1:110613. doi: 10.1016/j.radonc.2024.110613.
     PubMed     Abstract available
     
     
     October 2024
104. TATTENBERG S, Shin J, Hoehr C, Sung W, et al
     Correlation of dynamic blood dose with clinical outcomes in radiotherapy for head-and-neck cancer.
     Radiother Oncol. 2024 Oct 29:110603. doi: 10.1016/j.radonc.2024.110603.
     PubMed     Abstract available
     
     
     
105. GAITO S, Hwang E, Thwaites D, Ahern V, et al
     Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy.
     Radiother Oncol. 2024 Oct 26:110597. doi: 10.1016/j.radonc.2024.110597.
     PubMed     Abstract available
     
     
     
106. FELDMAN J, Pryanichnikov A, Shwartz D, Hillman Y, et al
     Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.
     Radiother Oncol. 2024;201:110572.
     PubMed     Abstract available
     
     
     
107. LIANG Z, Luo C, Li S, Zhu Y, et al
     Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect.
     Radiother Oncol. 2024 Oct 9:110571. doi: 10.1016/j.radonc.2024.110571.
     PubMed     Abstract available
     
     
     
108. ROJO-SANTIAGO J, Habraken SJM, Unipan M, Both S, et al
     A probabilistic evaluation of the Dutch robustness and model-based selection protocols for Head-and-Neck IMPT: A multi-institutional study.
     Radiother Oncol. 2024;199:110441.
     PubMed     Abstract available
     
     
     
109. PAN J, Qiu Z, Fu G, Liang J, et al
     Non-complete recovery of temporal lobe white matter diffusion metrics at one year Post-Radiotherapy: Implications for Radiation-Induced necrosis risk.
     Radiother Oncol. 2024;199:110420.
     PubMed     Abstract available
     
     
     
110. JOHNSON PB, Mamalui M, Brodin P, Janssens G, et al
     Secondary cancer risk in six anatomical sites when using PAT, IMPT, and VMAT/IMRT radiotherapy.
     Radiother Oncol. 2024;199:110421.
     PubMed     Abstract available
     
     
     September 2024
111. THIRUVENGADAM R, Kim SH, Thiruvengadam M
     Fructose 1,6-bisphosphate aldolase: A promising prognostic marker for oral cancer and its role in radiotherapy response.
     Radiother Oncol. 2024;200:110537.
     PubMed     Abstract available
     
     
     
112. DAVE J
     Concerns regarding the use of only phase 2 study to Justify palliative radiotherapy vs. Palliative chemo-radiotherapy in unresectable head and neck cancer.
     Radiother Oncol. 2024;200:110526.
     PubMed    
     
     
     
113. PODOBNIK G, Ibragimov B, Tappeiner E, Lee C, et al
     HaN-Seg: The head and neck organ-at-risk CT and MR segmentation challenge.
     Radiother Oncol. 2024;198:110410.
     PubMed     Abstract available
     
     
     
114. KONG W, Huiskes M, Habraken SJM, Astreinidou E, et al
     Reducing the lateral dose penumbra in IMPT by incorporating transmission pencil beams.
     Radiother Oncol. 2024;198:110388.
     PubMed     Abstract available
     
     
     August 2024
115. YANG Y, Shao R, Cao X, Chen M, et al
     Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials.
     Radiother Oncol. 2024;200:110517.
     PubMed     Abstract available
     
     
     
116. ZHU WY, Huang J, Lu ZQ, Yang S, et al
     Management of post-radiation carotid blowout syndrome in patients with head and neck cancer: A systematic review.
     Radiother Oncol. 2024;200:110502.
     PubMed     Abstract available
     
     
     
117. CHEN L, Wang H, Chen W, Li K, et al
     Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
     Radiother Oncol. 2024 Aug 25:110497. doi: 10.1016/j.radonc.2024.110497.
     PubMed     Abstract available
     
     
     
118. REINEMA FV, Hudson N, Adema GJ, Peeters WJM, et al
     MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.
     Radiother Oncol. 2024;200:110503.
     PubMed     Abstract available
     
     
     
119. BEUKEMA JC, Haveman JW, Langendijk JA, Oldehinkel E, et al
     Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.
     Radiother Oncol. 2024;200:110479.
     PubMed     Abstract available
     
     
     
120. TOPKAN E, Somay E, Selek U
     Comment on: Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
     Radiother Oncol. 2024;199:110467.
     PubMed    
     
     
     
121. BALAZS Z, Balermpas P, Ivankovic I, Willmann J, et al
     Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy.
     Radiother Oncol. 2024;197:110364.
     PubMed     Abstract available
     
     
     
122. MA B, Guo J, De Biase A, van Dijk LV, et al
     PET/CT based transformer model for multi-outcome prediction in oropharyngeal cancer.
     Radiother Oncol. 2024;197:110368.
     PubMed     Abstract available
     
     
     
123. AZEMAR N, Fontbonne C, Claude Quintyn J, Lebertz D, et al
     Assessment of gaze direction during head and neck irradiation and dosimetric impact on the retina, macula and papilla in a cohort of 240 patients with paraoptic tumors.
     Radiother Oncol. 2024;197:110342.
     PubMed     Abstract available
     
     
     
124. DOHOPOLSKI M, Visak J, Choi B, Meng B, et al
     In silico evaluation and feasibility of near margin-less head and neck daily adaptive radiotherapy.
     Radiother Oncol. 2024;197:110178.
     PubMed     Abstract available
     
     
     July 2024
125. SATO M, Hirose K
     A simple prediction model for the risk of boron neutron capture therapy-induced nausea and vomiting in head and neck cancer.
     Radiother Oncol. 2024;199:110464.
     PubMed     Abstract available
     
     
     
126. MENESES AG, Ferreira EB, Vieira LAC, Bontempo PSM, et al
     Comparison of liposomal gel with and without addition of chamomile for prevention of radiation dermatitis in head and neck cancer patients: A randomized controlled trial.
     Radiother Oncol. 2024;199:110440.
     PubMed     Abstract available
     
     
     
127. XIE C, Yu X, Tan N, Zhang J, et al
     Combined deep learning and radiomics in pretreatment radiation esophagitis prediction for patients with esophageal cancer underwent volumetric modulated arc therapy.
     Radiother Oncol. 2024;199:110438.
     PubMed     Abstract available
     
     
     
128. LI Y, van Rijn-Dekker MI, de Vette SPM, van der Schaaf A, et al
     Late-xerostomia prediction model based on (18)F-FDG PET image biomarkers of the main salivary glands.
     Radiother Oncol. 2024;196:110319.
     PubMed     Abstract available
     
     
     
129. ZUKAUSKAITE R, Kristensen MH, Eriksen JG, Johansen J, et al
     Comparison of 3-year local control using DAHANCA radiotherapy guidelines before and after implementation of five millimetres geometrical GTV to high-dose CTV margin.
     Radiother Oncol. 2024;196:110284.
     PubMed     Abstract available
     
     
     
130. CHIANG CL, Chan KSK, Li H, Ng WT, et al
     Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
     Radiother Oncol. 2024;196:110287.
     PubMed     Abstract available
     
     
     
131. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
     Response to letter to the editor by Somay et al., re: "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
     Radiother Oncol. 2024 Jul 1:110412. doi: 10.1016/j.radonc.2024.110412.
     PubMed    
     
     
     June 2024
132. NAVRAN A, Kayembe MT, Gouw ZAR, Vogel WV, et al
     FGD-PET/CT three months after (chemo)radiotherapy for head and neck squamous cell carcinoma spares considerable number of patients from a salvage neck dissection.
     Radiother Oncol. 2024;198:110407.
     PubMed     Abstract available
     
     
     
133. TOPKAN E, Somay E, Selek U
     Letter to the editor regarding "Risk factors associated with the development of osteoradionecrosis (ORN) in head and neck cancer patients in Ireland: A 10-year retrospective review".
     Radiother Oncol. 2024 Jun 25:110411. doi: 10.1016/j.radonc.2024.110411.
     PubMed    
     
     
     
134. CANTERS R, van der Klugt K, Trier Taasti V, Buijsen J, et al
     Robustness of intensity modulated proton treatment of esophageal cancer for anatomical changes and breathing motion.
     Radiother Oncol. 2024 Jun 23:110409. doi: 10.1016/j.radonc.2024.110409.
     PubMed     Abstract available
     
     
     
135. SATO M, Hirose K
     Efficacy and safety of boron neutron capture therapy for Hypopharyngeal/Laryngeal cancer patients with previous head and neck irradiation in Japan.
     Radiother Oncol. 2024 Jun 14:110382. doi: 10.1016/j.radonc.2024.110382.
     PubMed     Abstract available
     
     
     
136. MOORE-PALHARES D, Saifuddin M, Dasgupta A, Anzola Pena ML, et al
     Radiation enhancement using focussed ultrasound-stimulated microbubbles for head and neck cancer: A phase 1 clinical trial.
     Radiother Oncol. 2024;198:110380.
     PubMed     Abstract available
     
     
     
137. ZHOU H, Zhao Q, Huang W, Liang Z, et al
     A novel fully automatic segmentation and counting system for metastatic lymph nodes on multimodal magnetic resonance Imaging: Evaluation and prognostic implications in Nasopharyngeal carcinoma.
     Radiother Oncol. 2024 Jun 2:110367. doi: 10.1016/j.radonc.2024.110367.
     PubMed     Abstract available
     
     
     
138. YAZICI G, Kahvecioglu A, Yuce Sari S, Ozyigit G, et al
     Stereotactic radiotherapy for head and neck paragangliomas: How long should we wait for treatment response?
     Radiother Oncol. 2024;195:110232.
     PubMed     Abstract available
     
     
     
139. LIU YC, Zhang X, Yang HN, Zhang L, et al
     Proposals for the delineation of neck clinical target volume for definitive Radiation therapy in patients with oral/ oropharyngeal squamous cell cancer based on lymph node distribution.
     Radiother Oncol. 2024;195:110225.
     PubMed     Abstract available
     
     
     
140. MCCLURG DP, Sanghera C, Mukherjee S, Fitzgerald RC, et al
     A systematic review of circulating predictive and prognostic biomarkers to aid the personalised use of radiotherapy in the radical treatment of patients with oesophageal cancer.
     Radiother Oncol. 2024;195:110224.
     PubMed     Abstract available
     
     
     May 2024
141. JOSE BESSO M, Bitto V, Koi L, Wijaya Hadiwikarta W, et al
     Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
     Radiother Oncol. 2024 May 30:110348. doi: 10.1016/j.radonc.2024.110348.
     PubMed     Abstract available
     
     
     
142. SONG J, Yang X, Wu J, Wu Z, et al
     The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.
     Radiother Oncol. 2024 May 24:110340. doi: 10.1016/j.radonc.2024.110340.
     PubMed     Abstract available
     
     
     
143. ZHANG L, Jin S, Wang Y, Zhang Z, et al
     Predict nutrition-related adverse outcomes in head and neck cancer patients undergoing radiotherapy: A systematic review.
     Radiother Oncol. 2024 May 23:110339. doi: 10.1016/j.radonc.2024.110339.
     PubMed     Abstract available
     
     
     
144. NIELSEN CP, Lorenzen EL, Jensen K, Eriksen JG, et al
     Interobserver variation in organs at risk contouring in head and neck cancer according to the DAHANCA guidelines.
     Radiother Oncol. 2024;197:110337.
     PubMed    
     
     
     
145. BOREL C, Sun XS, Coutte A, Bera G, et al
     Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
     Radiother Oncol. 2024;197:110329.
     PubMed     Abstract available
     
     
     
146. ZHANG WW, Guo R
     Response to "Comments on 'Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study'".
     Radiother Oncol. 2024 May 11:110327. doi: 10.1016/j.radonc.2024.110327.
     PubMed    
     
     
     
147. ZHAN ZJ, Huang HY, Xiao YH, Zhao YP, et al
     Anxiety and depression in nasopharyngeal carcinoma patients and network analysis to identify central symptoms: A cross-sectional study from a high-incidence area.
     Radiother Oncol. 2024 May 10:110324. doi: 10.1016/j.radonc.2024.110324.
     PubMed     Abstract available
     
     
     
148. SHEN M, Lin X, Yang C, Zhou Z, et al
     Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
     Radiother Oncol. 2024 May 9:110323. doi: 10.1016/j.radonc.2024.110323.
     PubMed     Abstract available
     
     
     
149. HARDCASTLE N, Vasquez Osorio E, Jackson A, Mayo C, et al
     Multi-centre evaluation of variation in cumulative dose assessment in reirradiation scenarios.
     Radiother Oncol. 2024;194:110184.
     PubMed     Abstract available
     
     
     
150. SMITS HJG, Raaijmakers CPJ, de Ridder M, Gouw ZAR, et al
     Improved delineation with diffusion weighted imaging for laryngeal and hypopharyngeal tumors validated with pathology.
     Radiother Oncol. 2024;194:110182.
     PubMed     Abstract available
     
     
     
151. BOHLEN TT, Germond JF, Desorgher L, Veres I, et al
     Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy - An evaluation of dosimetric performances.
     Radiother Oncol. 2024;194:110177.
     PubMed     Abstract available
     
     
     
152. GAN Y, Langendijk JA, Oldehinkel E, Lin Z, et al
     Optimal timing of re-planning for head and neck adaptive radiotherapy.
     Radiother Oncol. 2024;194:110145.
     PubMed     Abstract available
     
     
     April 2024
153. XU L, Liu S, Yang Y, Shu L, et al
     LINC00313 suppresses autophagy and promotes stemness of nasopharyngeal carcinoma cells through PTBP1/STIM1 axis.
     Radiother Oncol. 2024;196:110310.
     PubMed     Abstract available
     
     
     
154. LIU Y, Ma J, Zeng XY, Zuo ZC, et al
     Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.
     Radiother Oncol. 2024;196:110311.
     PubMed     Abstract available
     
     
     
155. STARUCH M, Speth MM, Neyer P, Riesterer O, et al
     Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review.
     Radiother Oncol. 2024 Apr 20:110279. doi: 10.1016/j.radonc.2024.110279.
     PubMed     Abstract available
     
     
     
156. SELENGE BEDUK ESEN C, Nur Can G, Akkus Yildirim B
     Comments on "Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study".
     Radiother Oncol. 2024 Apr 20:110292. doi: 10.1016/j.radonc.2024.110292.
     PubMed    
     
     
     
157. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
     Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
     Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
     PubMed     Abstract available
     
     
     
158. ZHENG Z, Shen Y, Su J, Ji X, et al
     Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
     Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
     PubMed     Abstract available
     
     
     
159. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
     Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
     Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
     PubMed     Abstract available
     
     
     
160. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
     A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
     Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
     PubMed     Abstract available
     
     
     
161. SHUANG H, Feng J, Caineng C, Qifeng J, et al
     Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
     Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
     PubMed     Abstract available
     
     
     
162. CHOW JCH, Lee J, Lai MMP, Li S, et al
     Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
     Radiother Oncol. 2024;193:110143.
     PubMed     Abstract available
     
     
     
163. ZARINSHENAS R, Campbell P, Sun K, Molitoris JK, et al
     Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy.
     Radiother Oncol. 2024;193:110112.
     PubMed     Abstract available
     
     
     
164. ORLANDI E, Fontana G, Licitra L, Tinelli C, et al
     Comprehensive insights on the underlying potential and advantage of proton therapy over intensity-modulated photon radiation therapy as highlighted in a wide real world data analysis.
     Radiother Oncol. 2024;193:110122.
     PubMed    
     
     
     March 2024
165. DONG J, Ng WT, Wong CHL, Li JS, et al
     Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
     Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
     PubMed     Abstract available
     
     
     
166. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
     Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
     Radiother Oncol. 2024;195:110231.
     PubMed     Abstract available
     
     
     
167. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
     Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
     Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
     PubMed     Abstract available
     
     
     
168. BOON CS, Ramkumar S, Boon IS
     Proton beam radiotherapy head and neck cancer study design and endpoints.
     Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
     PubMed    
     
     
     
169. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
     Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
     Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
     PubMed     Abstract available
     
     
     
170. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
     Neurological complications of modern radiotherapy for head and neck cancer.
     Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
     PubMed     Abstract available
     
     
     
171. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
     Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
     Radiother Oncol. 2024;192:110109.
     PubMed     Abstract available
     
     
     
172. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
     Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
     Radiother Oncol. 2024;194:110189.
     PubMed     Abstract available
     
     
     February 2024
173. POPULAIRE P, Defraene G, Haustermans K
     Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
     Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
     PubMed    
     
     
     
174. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
     Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
     Radiother Oncol. 2024;194:110180.
     PubMed     Abstract available
     
     
     
175. BERBEE M, Muijs CT, Schuit E
     Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
     Radiother Oncol. 2024 Feb 17:110176. doi: 10.1016/j.radonc.2024.110176.
     PubMed    
     
     
     
176. FIORINO C, Palumbo D, Mori M, Palazzo G, et al
     Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
     Radiother Oncol. 2024;194:110160.
     PubMed     Abstract available
     
     
     
177. WANG X, Huang N, Yip PL, Wang J, et al
     The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population.
     Radiother Oncol. 2024;194:110154.
     PubMed     Abstract available
     
     
     
178. HORSHOLT KRISTENSEN M, Kristina Sorensen M, Tramm T, Alsner J, et al
     Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
     Radiother Oncol. 2024 Feb 8:110149. doi: 10.1016/j.radonc.2024.110149.
     PubMed     Abstract available
     
     
     
179. PERRIER L, Balusson F, Morelle M, Castelli J, et al
     Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
     Radiother Oncol. 2024;193:110116.
     PubMed     Abstract available
     
     
     
180. LINGE A, Patil S, Grosser M, Lohaus F, et al
     The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
     Radiother Oncol. 2024;191:110055.
     PubMed     Abstract available
     
     
     January 2024
181. FRANK MH, van Dijk BAC, Schoonbeek RC, Zindler J, et al
     Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.
     Radiother Oncol. 2024 Jan 21:110107. doi: 10.1016/j.radonc.2024.110107.
     PubMed     Abstract available
     
     
     
182. BLITZER GC, Paz C, Glassey A, Ganz OR, et al
     Functionality of Bone Marrow Mesenchymal Stromal Cells Derived from Head and Neck Cancer Patients - A FDA-IND Enabling Study Regarding MSC-based Treatments for Radiation-Induced Xerostomia.
     Radiother Oncol. 2024 Jan 13:110093. doi: 10.1016/j.radonc.2024.110093.
     PubMed     Abstract available
     
     
     
183. PIERIK AS, Poell JB, Brink A, Stigter-van Walsum M, et al
     Intratumor genetic heterogeneity and head and neck cancer relapse.
     Radiother Oncol. 2024 Jan 5:110087. doi: 10.1016/j.radonc.2024.110087.
     PubMed     Abstract available
     
     
     
184. WANG F, Zhou L, Zhang LJ, Xie CB, et al
     Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study.
     Radiother Oncol. 2024 Jan 5:110081. doi: 10.1016/j.radonc.2024.110081.
     PubMed     Abstract available
     
     
     
185. GUO Q, Lu T, Huang W, Xu H, et al
     Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.
     Radiother Oncol. 2024 Jan 4:110086. doi: 10.1016/j.radonc.2024.110086.
     PubMed     Abstract available
     
     
     
186. ZHONG Y, Lyu X, Huang M, Zheng L, et al
     Sole brachytherapy for inoperable, recurrent, and irradiated salivary gland cancer.
     Radiother Oncol. 2024;190:110022.
     PubMed     Abstract available
     
     
     
187. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
     Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
     Radiother Oncol. 2024;190:110036.
     PubMed    
     
     
     
188. SOMAY E, Yilmaz B, Topkan E
     Comments on "Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
     Radiother Oncol. 2024;190:110035.
     PubMed    
     
     
     
189. ZHU Y, Cheng J, Li Y, Pan D, et al
     Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
     Radiother Oncol. 2024;190:110033.
     PubMed     Abstract available
     
     
     
190. LIMKIN E, Blanchard P, Lacas B, Bourhis J, et al
     Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
     Radiother Oncol. 2024;190:110011.
     PubMed     Abstract available
     
     
     
191. RONCHI S, Cicchetti A, Bonora M, Ingargiola R, et al
     Curative carbon ion radiotherapy in a head and neck mucosal melanoma series: Facing the future within multidisciplinarity.
     Radiother Oncol. 2024;190:110003.
     PubMed     Abstract available
     
     
     
192. MUMAW DA, Hazy AJ, Vayntraub A, Quinn TJ, et al
     Low contralateral failure rate with unilateral proton beam radiotherapy for oropharyngeal squamous cell carcinoma: A multi-institutional prospective study from the proton collaborative group.
     Radiother Oncol. 2024;190:109977.
     PubMed     Abstract available
     
     
     December 2023
193. MURDAUGH DL, Milner D, Cardenas CE, Heinzman KA, et al
     Volumetric Brain Assessment of Long-Term Head and Neck Cancer Survivors.
     Radiother Oncol. 2023 Dec 22:110068. doi: 10.1016/j.radonc.2023.110068.
     PubMed     Abstract available
     
     
     
194. LIN CY, Chang CL, Lin KC, Chen WM, et al
     Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients.
     Radiother Oncol. 2023 Dec 22:110067. doi: 10.1016/j.radonc.2023.110067.
     PubMed     Abstract available
     
     
     
195. YU-CHEN, Luo MJ, Liu RP, Jin J, et al
     Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Dec 20:110051. doi: 10.1016/j.radonc.2023.110051.
     PubMed     Abstract available
     
     
     
196. AI QYH, King AD, Yuan H, Vardhanabhuti V, et al
     Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Dec 13:110050. doi: 10.1016/j.radonc.2023.110050.
     PubMed     Abstract available
     
     
     
197. BIRD D, Speight R, Andersson S, Wingqvist J, et al
     Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers.
     Radiother Oncol. 2023 Dec 12:110052. doi: 10.1016/j.radonc.2023.110052.
     PubMed     Abstract available
     
     
     
198. HABRICH J, Boeke S, Fritz V, Koerner E, et al
     Reproducibility of diffusion-weighted magnetic resonance imaging in head and neck cancer assessed on a 1.5 T MR-Linac and comparison to parallel measurements on a 3 T diagnostic scanner.
     Radiother Oncol. 2023 Dec 7:110046. doi: 10.1016/j.radonc.2023.110046.
     PubMed     Abstract available
     
     
     
199. MARIA HUYNH TT, Dale E, Sorum Falk R, Paulsen Hellebust T, et al
     Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters.
     Radiother Oncol. 2023 Dec 5:110044. doi: 10.1016/j.radonc.2023.110044.
     PubMed     Abstract available
     
     
     
200. MISZCZYK M, Suleja A, Sobel S, Stec M, et al
     Salvage re-irradiation in non-melanoma skin cancers: A multicenter analysis.
     Radiother Oncol. 2023;189:109945.
     PubMed     Abstract available
     
     
     
201. HOU Z, Guo Y, Shen X, Dong B, et al
     Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
     Radiother Oncol. 2023;189:109937.
     PubMed     Abstract available
     
     
     
202. TSAI MH, Chang JTC, Lu HH, Wu YH, et al
     Development and validation of a machine learning model of radiation-induced hypothyroidism with clinical and dose-volume features.
     Radiother Oncol. 2023;189:109911.
     PubMed     Abstract available
     
     
     November 2023
203. MENG Z, Li P, Yang D, Huang H, et al
     The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
     Radiother Oncol. 2023 Nov 24:110027. doi: 10.1016/j.radonc.2023.110027.
     PubMed     Abstract available
     
     
     
204. SOMAY E, Topkan E, Selek U
     Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
     Radiother Oncol. 2023 Nov 24:110025. doi: 10.1016/j.radonc.2023.110025.
     PubMed    
     
     
     
205. BUURMAN DJM, Speksnijder CM, Granzier ME, Timmer VCML, et al
     Response to: Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
     Radiother Oncol. 2023 Nov 24:110026. doi: 10.1016/j.radonc.2023.110026.
     PubMed    
     
     
     
206. DELERUE C, Pasquier D, Bogart E, Mirabel X, et al
     Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.
     Radiother Oncol. 2023;190:110029.
     PubMed     Abstract available
     
     
     
207. HUANG CL, Wang GY, Lou JH, Chen L, et al
     Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
     Radiother Oncol. 2023;190:110032.
     PubMed     Abstract available
     
     
     
208. BERBEE M, Muijs CT, Voncken FEM, Wee LS, et al
     External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
     Radiother Oncol. 2023 Nov 8:109979. doi: 10.1016/j.radonc.2023.109979.
     PubMed     Abstract available
     
     
     
209. HR M, P P, L H, Ds M, et al
     PROton versus photon Therapy for Esophageal Cancer - a Trimodality strategy (PROTECT) NCT050555648.
     Radiother Oncol. 2023 Nov 5:109980. doi: 10.1016/j.radonc.2023.109980.
     PubMed    
     
     
     
210. CHEN L, Li J, Li K, Hu J, et al
     Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy.
     Radiother Oncol. 2023 Nov 3:109985. doi: 10.1016/j.radonc.2023.109985.
     PubMed     Abstract available
     
     
     
211. KIM K, Oh D, Myoung Noh J, Won Min Y, et al
     Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis.
     Radiother Oncol. 2023 Nov 3:109982. doi: 10.1016/j.radonc.2023.109982.
     PubMed     Abstract available
     
     
     
212. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
     Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
     Radiother Oncol. 2023;188:109889.
     PubMed     Abstract available
     
     
     
213. CASS S, Cope B, Bishop AJ, Chiang YJ, et al
     Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.
     Radiother Oncol. 2023;188:109892.
     PubMed     Abstract available
     
     
     October 2023
214. HE YQ, Wang TM, Yang DW, Xue WQ, et al
     A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Oct 30:109974. doi: 10.1016/j.radonc.2023.109974.
     PubMed     Abstract available
     
     
     
215. AMSTUTZ F, Krcek R, Bachtiary B, Weber DC, et al
     Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - from a fixed beam line to an arc.
     Radiother Oncol. 2023 Oct 30:109973. doi: 10.1016/j.radonc.2023.109973.
     PubMed     Abstract available
     
     
     
216. CHANG CL, Lin KC, Chen WM, Shia BC, et al
     Comparing the Oncologic Outcomes of Proton Therapy and Intensity-Modulated Radiation Therapy for Head and Neck Squamous Cell Carcinoma.
     Radiother Oncol. 2023 Oct 28:109971. doi: 10.1016/j.radonc.2023.109971.
     PubMed     Abstract available
     
     
     
217. FRIBORG J, Jensen K, Eriksen JG, Samsoe E, et al
     Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
     Radiother Oncol. 2023 Oct 21:109958. doi: 10.1016/j.radonc.2023.109958.
     PubMed     Abstract available
     
     
     
218. CHEN AM
     Management of Unknown Primary Head and Neck Cancer with Radiation Therapy in the Era of Human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple.
     Radiother Oncol. 2023 Oct 14:109952. doi: 10.1016/j.radonc.2023.109952.
     PubMed     Abstract available
     
     
     
219. GAI X, Su L, Huang S, Zeng J, et al
     Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
     Radiother Oncol. 2023 Oct 7:109942. doi: 10.1016/j.radonc.2023.109942.
     PubMed     Abstract available
     
     
     
220. LI S, Zhang W, Liang B, Huang W, et al
     A Rulefit-Based Prognostic Analysis Using Structured MRI Report to Select Potential Beneficiaries from Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Dual-Centre Study.
     Radiother Oncol. 2023 Oct 7:109943. doi: 10.1016/j.radonc.2023.109943.
     PubMed     Abstract available
     
     
     
221. LIN CH, Yan JL, Yap WK, Kang CJ, et al
     Prognostic Value of Interim CT-based Peritumoral and Intratumoral Radiomics in Laryngeal and Hypopharyngeal Cancer Patients Undergoing Definitive Radiotherapy.
     Radiother Oncol. 2023 Oct 6:109938. doi: 10.1016/j.radonc.2023.109938.
     PubMed     Abstract available
     
     
     
222. SUN XS, Wang JW, Han F, Zou RH, et al
     Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.
     Radiother Oncol. 2023 Oct 6:109939. doi: 10.1016/j.radonc.2023.109939.
     PubMed     Abstract available
     
     
     
223. AHERN V, Adeberg S, Fossati P, Garrett R, et al
     An international approach to estimating the indications and number of eligible patients for carbon ion radiation therapy (CIRT) in Australia.
     Radiother Oncol. 2023;187:109816.
     PubMed     Abstract available
     
     
     September 2023
224. YEONG SONG J, Sung Ho M, Suh YG, Kim JH, et al
     Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10).
     Radiother Oncol. 2023 Sep 30:109936. doi: 10.1016/j.radonc.2023.109936.
     PubMed     Abstract available
     
     
     
225. BOLLEN H, Gulyban A, Nuyts S
     Impact of consensus guidelines on delineation of primary tumor Clinical Target Volume (CTVp) for head and neck cancer: results of a national review project.
     Radiother Oncol. 2023 Sep 20:109915. doi: 10.1016/j.radonc.2023.109915.
     PubMed     Abstract available
     
     
     
226. LIU S, Zou Y, Zhong M, Li T, et al
     Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
     Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
     PubMed     Abstract available
     
     
     
227. YAN W, Liu T, He M, Yi J, et al
     Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
     Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
     PubMed     Abstract available
     
     
     
228. LI D, Yang LN, Lin JY, Wu YZ, et al
     Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
     Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
     PubMed     Abstract available
     
     
     August 2023
229. OZER O, Shafi H, O'Reilly D, Loiseau C, et al
     Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
     Radiother Oncol. 2023 Aug 31:109895. doi: 10.1016/j.radonc.2023.109895.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.